other carriers to the National Register of Historic Places, National Park Service, 1849 C Street NW, MS 7228, Washington, DC 20240.

SUPPLEMENTARY INFORMATION: The properties listed in this notice are being considered for listing or related actions in the National Register of Historic Places. Nominations for their consideration were received by the National Park Service before November 21, 2020. Pursuant to Section 60.13 of 36 CFR part 60, comments are being accepted concerning the significance of the nominated properties under the National Register criteria for evaluation.

Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

Nominations submitted by State or Tribal Historic Preservation Officers:

CALIFORNIA

Alameda County

Hotel Menlo, 344 13th St., Oakland, SG100005984

COLORADO

Bent County

Boggsville (Boundary Increase), 2 mi. south of Las Animas, east of CO 101, Las Animas vicinity, BC100005980

Gilpin County

Frontenac and Aduddell Mine Complex, (Mining Industry in Colorado, MPS), 0.25 mi. southwest of jct. of Church Placer and Pewabic Mountain Rds., Russell Gulch vicinity, MP100005981

ILLINOIS

Crawford County

Allen, Dr. Arthur W., Home, 11266 North Trimble Rd., Robinson, SG100005966

Douglas County

Henson House, 103 North Henson Rd., Villa Grove, SG100005967

Jersey County

Jerseyville First Presbyterian Church, 400 South State St., Jerseyville, SG100005968

Winnebago County

Rockford Woman's Club, 323 Park Ave., Rockford, SG100005971

MARYLAND

Frederick County

Ceres Bethel AME Church, Gapland Rd., approx. 2 mi. west of Burkittsville, Burkittsville vicinity, SG100005982

MICHIGAN

Wayne County

United States Postal Service Roosevelt Park Station, 1800 18th St., Detroit, SG100005983

NEW YORK

Madison County

Oneida Community Limited Administration Building, 181 Kenwood Ave., Oneida, SG100005960

Washington County

Greenwich District School No. 11, 4 Ryan Rd., Center Falls, SG100005961

NORTH CAROLINA

Granville County

Oxford Historic District (Boundary Increase and Decrease), (Granville County MPS), Roughly bounded by Alexander and Sunset Aves., 3rd, Belle, Broad, Cherry, College, Devin, Franklin, Front, Gilliam, Granville, Henderson, Hillsboro, Lanier, Main, New College, Raleigh, and West Sts., and Martin Luther King Jr. Blvd., Oxford, BC100005974

Hertford County

Winton Historic District, Roughly bounded by west side of North King St., north of Cross St., North Murfree, East Weaver, and West Jordan Sts., Winton, SG100005976

Surry County

Country Club Estates Historic District, Includes portions of Club View Dr., Country Club Rd., Fairway Ln., and Greenhill Rd., Mount Airy, SG100005977

Lebanon Hill Historic District, Roughly bounded by Howard, Mitchell, South, and Woodruff Sts., and the Mount Airy Historic District, Mount Airy, SG100005978

In the interest of preservation, a SHORTENED comment period has been requested for the following resource:

MARYLAND

Kent County

Piney Grove, 7281 Wilkins Ln., Chestertown, SG100005962

Comment period: 3 days

A request to move has been received for the following resource:

NORTH CAROLINA

Alamance County

Menagerie Carousel, Burlington City Park, South Main St., Burlington, MV82003420

Additional documentation has been received for the following resources:

COLORADO

Bent County

Boggsville (Additional Documentation), South of Las Animas on CO 101, Las Animas vicinity, AD86002841

ILLINOIS

Wayne County

Turney-Hall House (Additional Documentation), 502 SE 4th St., Fairfield, AD100002329

Will County

Plainfield Halfway House (Additional Documentation), 503 Main St., Plainfield, AD80001421

NORTH CAROLINA

Granville County

Oxford Historic District (Additional Documentation), (Granville County MPS), Roughly bounded by College, New College, Gilliam, Raleigh, Front, Broad, Goshen, and Hayes Sts., Oxford, AD88000403

Authority: Section 60.13 of 36 CFR part 60.

Dated: November 24, 2024.

Sherry A. Frear,

Chief, National Register of Historic Places/ National Historic Landmarks Program.

[FR Doc. 2020–26616 Filed 12–2–20; 8:45 am]

BILLING CODE 4312–52–P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Subcutaneous Drug Development & Delivery Consortium, Inc.

Notice is hereby given that, on October 26, 2020, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (''the Act''), Subcutaneous Drug Development & Delivery Consortium, Inc. (''Subcutaneous Drug Development & Delivery Consortium, Inc.'') has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to Section 6(b) of the Act, the identity of the parties to the venture are: Eli Lilly and Company, Indianapolis, IN; Halozyme, Inc., San Diego, CA; Bristol Myers Squibb, New Brunswick, NJ; AstraZeneca, San Francisco, CA; and Amgen Inc., Thousand Oaks, CA. The general area of Subcutaneous Drug Development & Delivery Consortium, Inc.'s planned activity is (a) transform patient care and improve patient outcomes by identifying and addressing key gaps, unmet needs and actionable issues in the dynamic subcutaneous (''SC'') drug delivery and development landscape, including through research, publication of industry analyses, and the

development of SC-related manuscripts, models, standards and other guidance materials (collectively, ''Guidance''); (b) provide a venue for reviewing, developing, maintaining and supporting the Guidance; (c) promote the Guidance worldwide; (d) provide for testing and conformity assessment of implementations in order to ensure and/or facilitate compliance with Guidance; (e) operate a branding program based upon distinctive trademarks to create high customer awareness of, demand for, and confidence in the Guidance, and products or services designed in compliance therewith; and (f) undertake such other activities as may from time to time be appropriate to further the purposes and achieve the goals set forth above.

Membership in Subcutaneous Drug Development & Delivery Consortium, Inc. remains open and Subcutaneous Drug Development & Delivery Consortium, Inc. intends to file additional written notifications disclosing all changes in membership.

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2020–26626 Filed 12–2–20; 8:45 am]

BILLING CODE 4410–11–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–750]

Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Janssen Pharmaceuticals Inc., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before February 1, 2021. Such persons may also file a written request for a hearing on the application on or before February 1, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on November 11, 2020, Janssen Pharmaceuticals Inc., 1440 Olympic Drive, Athens, Georgia, 30601–1645, applied to be registered as an bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Methylphenidate	1724	II
Hydromorphone	9150	II
Hydrocodone	9193	II
Oripavine	9330	II
Thebaine	9333	II
Tapentadol	9780	II

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2020–26651 Filed 12–2–20; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Federal Bureau of Investigation

[OMB Number 1110–0051]

Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Currently Approved Collection; Final Disposition Report (R–84), With Supplemental Questions R–84(a), R–84(b), R–84(c), R–84(d), R–84(e), R–84(f), R–84(g), R–84(h), R–84(i), and R–84(j)

AGENCY: Criminal Justice Information Services Division, Federal Bureau of Investigation, Department of Justice.

ACTION: 30-day notice.

SUMMARY: The Criminal Justice Information Services (CJIS) Division, Federal Bureau of Investigation (FBI), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

DATES: Comments are encouraged and will be accepted for an additional 30 days until January 4, 2021.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function.

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

—Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

—Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and

—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.,* permitting electronic submission of responses.

Overview of This Information Collection

(1) *Type of Information Collection:* Revision of a currently approved collection.

(2) *Title of the Form/Collection:* Final Disposition Report.

(3) Agency form number, if any, and the applicable component of the Department sponsoring the collection:

Agency form number: R–84, with supplemental questions R–84(a), R–84(b), R–84(c), R–84(d), R–84(e), R–84(f), R–84(g), R–84(h), R–84(i), and R–84(j).

Sponsoring component: Department of Justice, Criminal Justice Information Services Division.

(4) Affected public who will be asked or required to respond, as well as a brief abstract: *Primary:* City, county, state, federal and tribal law enforcement agencies. This collection is needed to report completion of an arrest event. Acceptable data is stored as part of the Next Generation Identification (NGI) system of the FBI.

(5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply: It is estimated that 75,605 respondents will complete each form within approximately 5 minutes.